Levosimendan vs. Dobutamine: Outcomes for Acute Heart Failure Patients on β-Blockers in SURVIVE

Alexandre Mebazaa(Délégation Paris 5), Alain Cohen‐Solal(Hôpital Lariboisière), Jeffrey E. Salon(Abbott (United Kingdom)), Markku S. Nieminen(Cornell University), Robert J. Padley(Abbott (United Kingdom)), Bidan Huang(AbbVie (United States)), John G.F. Cleland(University of Glasgow), Roopal Thakkar(Abbott (United Kingdom)), Gerasimos Filippatos(University General Hospital Attikon)

European Journal of Heart Failure

January 21, 2009

10.1093/eurjhf/hfn045

Cited by 193

Related Papers

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

|European Heart Journal|2021|13.1k

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|5.4k

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

|New England Journal of Medicine|2021|4.6k

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

|The Lancet|2003|3.8k

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

|European Heart Journal|2011|3.5k